No Cover Image

Journal article 503 views 67 downloads

Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK

Christian Schnier, Aoife McCarthy, Daniel R Morales, Ashley Akbari Orcid Logo, Reecha Sofat, Caroline Dale, Rohan Takhar, Mamas A Mamas, Kamlesh Khunti, Francesco Zaccardi, Cathie LM Sudlow, Tim Wilkinson

The Lancet Healthy Longevity, Volume: 4, Issue: 8, Pages: e421 - e430

Swansea University Author: Ashley Akbari Orcid Logo

  • 64020.VOR.pdf

    PDF | Version of Record

    © 2023 The Author(s). Published by Elsevier Ltd. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).

    Download (1MB)

Check full text

DOI (Published version): 10.1016/s2666-7568(23)00105-8

Abstract

Background: Concerns have been raised that antipsychotic drug prescribing, which has been associated with increased mortality in people with dementia, might have increased during the COVID-19 pandemic due to social restrictions imposed to limit the spread of SARS-CoV-2. We used multisource, routinel...

Full description

Published in: The Lancet Healthy Longevity
ISSN: 2666-7568
Published: Elsevier BV 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa64020
first_indexed 2023-09-13T15:20:51Z
last_indexed 2024-11-25T14:13:17Z
id cronfa64020
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2023-12-04T16:49:30.1930947</datestamp><bib-version>v2</bib-version><id>64020</id><entry>2023-08-03</entry><title>Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK</title><swanseaauthors><author><sid>aa1b025ec0243f708bb5eb0a93d6fb52</sid><ORCID>0000-0003-0814-0801</ORCID><firstname>Ashley</firstname><surname>Akbari</surname><name>Ashley Akbari</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-08-03</date><deptcode>MEDS</deptcode><abstract>Background: Concerns have been raised that antipsychotic drug prescribing, which has been associated with increased mortality in people with dementia, might have increased during the COVID-19 pandemic due to social restrictions imposed to limit the spread of SARS-CoV-2. We used multisource, routinely collected health-care data from Wales, UK to investigate prescribing and mortality variations in people with dementia before and during the COVID-19 pandemic. Methods: In this retrospective cohort study, we used individual-level, anonymised, population-scale linked health data to identify adults aged 60 years and older with a diagnosis of dementia in Wales, UK. We used the CVD-COVID-UK initiative to access Welsh routinely collected electronic health record data from the Secure Anonymised Information Linkage (SAIL) Databank. Patients who were alive and registered with a SAIL general practice on Jan 1, 2016, and who received a dementia diagnosis before the age of 60 years and before or during the study period were included. We explored antipsychotic drug prescribing rate changes over 67 months, between Jan 1, 2016, and Aug 1, 2021, overall and stratified by age and dementia subtype. We used time-series analyses to examine all-cause and myocardial infarction and stroke mortality over the study period and identified the leading causes of death in people with dementia between Jan 1, 2020, and Aug 1, 2021. Findings: Of 3&#x2008;106&#x2008;690 participants in SAIL between Jan 1, 2016 and Aug 1, 2021, 57&#x2008;396 people (35&#x2008;148 [61&#xB7;2%] women and 22&#x2008;248 [38&#xB7;8%] men) met inclusion criteria for this study and contributed 101&#x2008;428 person-years of follow-up. Of the 57&#x2008;396 people with dementia, 11&#x2008;929 (20&#xB7;8%) were prescribed an antipsychotic drug at any point during follow-up. Accounting for seasonality, antipsychotic drug prescribing increased during the second half of 2019 and throughout 2020. However, the absolute difference in prescribing rates was small, ranging from 1253 prescriptions per 10&#x2008;000 person-months in March, 2019, to 1305 per 10&#x2008;000 person-months in September, 2020. All-cause mortality and stroke mortality increased throughout 2020, while myocardial infarction mortality declined. From Jan 1, 2020, to Aug 1, 2021, 1286 (17&#xB7;1%) of 7508 participants who died had COVID-19 recorded as the underlying cause of death. Interpretation: During the COVID-19 pandemic, antipsychotic drug prescribing in people with dementia in the UK increased slightly; however, it is unlikely that this was solely related to the pandemic and this increase was unlikely to be a major factor in the substantial increase in mortality during 2020. The long-term increase in antipsychotic drug prescribing in younger people and in those with Alzheimer's disease warrants further investigation using resources with access to more granular clinical data. Although deprescribing antipsychotic medications remains an essential aspect of dementia care, the results of this study suggest that changes in prescribing and deprescribing practices as a result of the COVID-19 pandemic are not required.</abstract><type>Journal Article</type><journal>The Lancet Healthy Longevity</journal><volume>4</volume><journalNumber>8</journalNumber><paginationStart>e421</paginationStart><paginationEnd>e430</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2666-7568</issnElectronic><keywords>Antipsychotic drug, dementia, COVID-19, pandemic, SAIL databank</keywords><publishedDay>3</publishedDay><publishedMonth>8</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-08-03</publishedDate><doi>10.1016/s2666-7568(23)00105-8</doi><url>http://dx.doi.org/10.1016/s2666-7568(23)00105-8</url><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>British Heart Foundation (via the British Heart Foundation Data Science Centre led by Health Data Research UK (grant number SP/19/3/34678)), and the Scottish Neurological Research Fund.</funders><projectreference/><lastEdited>2023-12-04T16:49:30.1930947</lastEdited><Created>2023-08-03T08:45:49.1530163</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Health Data Science</level></path><authors><author><firstname>Christian</firstname><surname>Schnier</surname><order>1</order></author><author><firstname>Aoife</firstname><surname>McCarthy</surname><order>2</order></author><author><firstname>Daniel R</firstname><surname>Morales</surname><order>3</order></author><author><firstname>Ashley</firstname><surname>Akbari</surname><orcid>0000-0003-0814-0801</orcid><order>4</order></author><author><firstname>Reecha</firstname><surname>Sofat</surname><order>5</order></author><author><firstname>Caroline</firstname><surname>Dale</surname><order>6</order></author><author><firstname>Rohan</firstname><surname>Takhar</surname><order>7</order></author><author><firstname>Mamas A</firstname><surname>Mamas</surname><order>8</order></author><author><firstname>Kamlesh</firstname><surname>Khunti</surname><order>9</order></author><author><firstname>Francesco</firstname><surname>Zaccardi</surname><order>10</order></author><author><firstname>Cathie LM</firstname><surname>Sudlow</surname><order>11</order></author><author><firstname>Tim</firstname><surname>Wilkinson</surname><order>12</order></author></authors><documents><document><filename>64020__28534__0023d409c42d4514bc86bfc6c7688227.pdf</filename><originalFilename>64020.VOR.pdf</originalFilename><uploaded>2023-09-13T16:15:08.2403820</uploaded><type>Output</type><contentLength>1052293</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2023 The Author(s). Published by Elsevier Ltd. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2023-12-04T16:49:30.1930947 v2 64020 2023-08-03 Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK aa1b025ec0243f708bb5eb0a93d6fb52 0000-0003-0814-0801 Ashley Akbari Ashley Akbari true false 2023-08-03 MEDS Background: Concerns have been raised that antipsychotic drug prescribing, which has been associated with increased mortality in people with dementia, might have increased during the COVID-19 pandemic due to social restrictions imposed to limit the spread of SARS-CoV-2. We used multisource, routinely collected health-care data from Wales, UK to investigate prescribing and mortality variations in people with dementia before and during the COVID-19 pandemic. Methods: In this retrospective cohort study, we used individual-level, anonymised, population-scale linked health data to identify adults aged 60 years and older with a diagnosis of dementia in Wales, UK. We used the CVD-COVID-UK initiative to access Welsh routinely collected electronic health record data from the Secure Anonymised Information Linkage (SAIL) Databank. Patients who were alive and registered with a SAIL general practice on Jan 1, 2016, and who received a dementia diagnosis before the age of 60 years and before or during the study period were included. We explored antipsychotic drug prescribing rate changes over 67 months, between Jan 1, 2016, and Aug 1, 2021, overall and stratified by age and dementia subtype. We used time-series analyses to examine all-cause and myocardial infarction and stroke mortality over the study period and identified the leading causes of death in people with dementia between Jan 1, 2020, and Aug 1, 2021. Findings: Of 3 106 690 participants in SAIL between Jan 1, 2016 and Aug 1, 2021, 57 396 people (35 148 [61·2%] women and 22 248 [38·8%] men) met inclusion criteria for this study and contributed 101 428 person-years of follow-up. Of the 57 396 people with dementia, 11 929 (20·8%) were prescribed an antipsychotic drug at any point during follow-up. Accounting for seasonality, antipsychotic drug prescribing increased during the second half of 2019 and throughout 2020. However, the absolute difference in prescribing rates was small, ranging from 1253 prescriptions per 10 000 person-months in March, 2019, to 1305 per 10 000 person-months in September, 2020. All-cause mortality and stroke mortality increased throughout 2020, while myocardial infarction mortality declined. From Jan 1, 2020, to Aug 1, 2021, 1286 (17·1%) of 7508 participants who died had COVID-19 recorded as the underlying cause of death. Interpretation: During the COVID-19 pandemic, antipsychotic drug prescribing in people with dementia in the UK increased slightly; however, it is unlikely that this was solely related to the pandemic and this increase was unlikely to be a major factor in the substantial increase in mortality during 2020. The long-term increase in antipsychotic drug prescribing in younger people and in those with Alzheimer's disease warrants further investigation using resources with access to more granular clinical data. Although deprescribing antipsychotic medications remains an essential aspect of dementia care, the results of this study suggest that changes in prescribing and deprescribing practices as a result of the COVID-19 pandemic are not required. Journal Article The Lancet Healthy Longevity 4 8 e421 e430 Elsevier BV 2666-7568 Antipsychotic drug, dementia, COVID-19, pandemic, SAIL databank 3 8 2023 2023-08-03 10.1016/s2666-7568(23)00105-8 http://dx.doi.org/10.1016/s2666-7568(23)00105-8 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee British Heart Foundation (via the British Heart Foundation Data Science Centre led by Health Data Research UK (grant number SP/19/3/34678)), and the Scottish Neurological Research Fund. 2023-12-04T16:49:30.1930947 2023-08-03T08:45:49.1530163 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Health Data Science Christian Schnier 1 Aoife McCarthy 2 Daniel R Morales 3 Ashley Akbari 0000-0003-0814-0801 4 Reecha Sofat 5 Caroline Dale 6 Rohan Takhar 7 Mamas A Mamas 8 Kamlesh Khunti 9 Francesco Zaccardi 10 Cathie LM Sudlow 11 Tim Wilkinson 12 64020__28534__0023d409c42d4514bc86bfc6c7688227.pdf 64020.VOR.pdf 2023-09-13T16:15:08.2403820 Output 1052293 application/pdf Version of Record true © 2023 The Author(s). Published by Elsevier Ltd. Distributed under the terms of a Creative Commons Attribution 4.0 License (CC BY 4.0). true eng https://creativecommons.org/licenses/by/4.0/
title Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
spellingShingle Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
Ashley Akbari
title_short Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
title_full Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
title_fullStr Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
title_full_unstemmed Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
title_sort Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK
author_id_str_mv aa1b025ec0243f708bb5eb0a93d6fb52
author_id_fullname_str_mv aa1b025ec0243f708bb5eb0a93d6fb52_***_Ashley Akbari
author Ashley Akbari
author2 Christian Schnier
Aoife McCarthy
Daniel R Morales
Ashley Akbari
Reecha Sofat
Caroline Dale
Rohan Takhar
Mamas A Mamas
Kamlesh Khunti
Francesco Zaccardi
Cathie LM Sudlow
Tim Wilkinson
format Journal article
container_title The Lancet Healthy Longevity
container_volume 4
container_issue 8
container_start_page e421
publishDate 2023
institution Swansea University
issn 2666-7568
doi_str_mv 10.1016/s2666-7568(23)00105-8
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Health Data Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Health Data Science
url http://dx.doi.org/10.1016/s2666-7568(23)00105-8
document_store_str 1
active_str 0
description Background: Concerns have been raised that antipsychotic drug prescribing, which has been associated with increased mortality in people with dementia, might have increased during the COVID-19 pandemic due to social restrictions imposed to limit the spread of SARS-CoV-2. We used multisource, routinely collected health-care data from Wales, UK to investigate prescribing and mortality variations in people with dementia before and during the COVID-19 pandemic. Methods: In this retrospective cohort study, we used individual-level, anonymised, population-scale linked health data to identify adults aged 60 years and older with a diagnosis of dementia in Wales, UK. We used the CVD-COVID-UK initiative to access Welsh routinely collected electronic health record data from the Secure Anonymised Information Linkage (SAIL) Databank. Patients who were alive and registered with a SAIL general practice on Jan 1, 2016, and who received a dementia diagnosis before the age of 60 years and before or during the study period were included. We explored antipsychotic drug prescribing rate changes over 67 months, between Jan 1, 2016, and Aug 1, 2021, overall and stratified by age and dementia subtype. We used time-series analyses to examine all-cause and myocardial infarction and stroke mortality over the study period and identified the leading causes of death in people with dementia between Jan 1, 2020, and Aug 1, 2021. Findings: Of 3 106 690 participants in SAIL between Jan 1, 2016 and Aug 1, 2021, 57 396 people (35 148 [61·2%] women and 22 248 [38·8%] men) met inclusion criteria for this study and contributed 101 428 person-years of follow-up. Of the 57 396 people with dementia, 11 929 (20·8%) were prescribed an antipsychotic drug at any point during follow-up. Accounting for seasonality, antipsychotic drug prescribing increased during the second half of 2019 and throughout 2020. However, the absolute difference in prescribing rates was small, ranging from 1253 prescriptions per 10 000 person-months in March, 2019, to 1305 per 10 000 person-months in September, 2020. All-cause mortality and stroke mortality increased throughout 2020, while myocardial infarction mortality declined. From Jan 1, 2020, to Aug 1, 2021, 1286 (17·1%) of 7508 participants who died had COVID-19 recorded as the underlying cause of death. Interpretation: During the COVID-19 pandemic, antipsychotic drug prescribing in people with dementia in the UK increased slightly; however, it is unlikely that this was solely related to the pandemic and this increase was unlikely to be a major factor in the substantial increase in mortality during 2020. The long-term increase in antipsychotic drug prescribing in younger people and in those with Alzheimer's disease warrants further investigation using resources with access to more granular clinical data. Although deprescribing antipsychotic medications remains an essential aspect of dementia care, the results of this study suggest that changes in prescribing and deprescribing practices as a result of the COVID-19 pandemic are not required.
published_date 2023-08-03T20:23:48Z
_version_ 1821347810884190208
score 11.04748

Similar Items